Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

This study employs a prospective, multicenter, randomized, two-arm design aimed at evaluating the efficacy and safety of the FTO regimen in preventing delayed chemotherapy-induced nausea and vomiting (CINV) following high-dose chemotherapy for hematopoietic stem cell transplantation (HSCT). A total of 92 patients with multiple myeloma who were indicated for autologous HSCT were enrolled. The primary endpoint was to compare the complete response (CR) rates of the FTO regimen versus the FTD regimen in the delayed phase (24-240 hours after chemotherapy) for preventing nausea and vomiting induced by high-dose chemotherapy during HSCT.

NCT Number	NCT07413809
Lead Sponsor	The Affiliated People's Hospital of Ningbo University Collaborators: Zhejiang University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City, Jinhua Central Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital, Jinhua People's Hospital, Zhejiang Provincial Tongde Hospital, First Affiliated Hospital of Wenzhou Medical University, Dongyang People's Hospital, Taizhou Hospital
Conditions	Multiple Myeloma
Enrollment	92 participants
Start Date	2025-10-31
Primary Completion	2027-09 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2026-02-17